Maxcyte (MXCT) Total Liabilities (2019 - 2026)

Maxcyte (MXCT) has 8 years of Total Liabilities data on file, last reported at $26.6 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $26.6 million, down 12.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.6 million (down 12.97% YoY), and the FY2025 annual result was $31.0 million, down 6.63% from the prior year.
• Total Liabilities slipped to $26.6 million in Q1 2026 per MXCT's latest filing, from $31.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $36.1 million in Q4 2023 and troughed at $26.6 million in Q1 2026.
• A 5-year average of $31.8 million and a median of $32.0 million in 2022 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 135.6% in 2022, then fell 12.97% in 2026.
• A 5-year view of Total Liabilities shows it stood at $32.7 million in 2022, then gained by 10.47% to $36.1 million in 2023, then retreated by 8.0% to $33.2 million in 2024, then slipped by 6.63% to $31.0 million in 2025, then decreased by 14.28% to $26.6 million in 2026.
• Business Quant data shows MXCT's Total Liabilities at $26.6 million in Q1 2026, $31.0 million in Q4 2025, and $33.2 million in Q3 2025.